|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | European Organization for Research and Treatment of Cancer |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00045019 |
Purpose
RATIONALE: Questionnaires may help determine cancer patients' satisfaction with the quality of care they received in the hospital.
PURPOSE: Clinical trial to determine the effectiveness of questionnaires in assessing cancer patients' satisfaction with the quality of care they received in the hospital.
| Condition | Intervention |
|---|---|
|
Unspecified Adult Solid Tumor, Protocol Specific |
Procedure: quality-of-life assessment |
| Study Type: | Interventional |
| Study Design: | Non-Randomized, Active Control |
| Official Title: | An International Field-Testing Study Of The Reliability And Validity Of A Patient Satisfaction Module (QLQ-SAT32) Assessing Cancer Patients' Perception Of The Quality Of Care Received Within The Hospital |
| Study Start Date: | May 2002 |
OBJECTIVES:
OUTLINE: This is a descriptive, multicenter study. Patients are stratified according to age (18 to 49 vs 50 and over) and the cancer therapy received in hospital (surgery vs chemotherapy).
Patients in all strata receive the QLQ-SAT32 and QLQ-C30 questionnaires, a debriefing questionnaire, and the Oberst patient satisfaction visual analog scale prior to hospital discharge. Patients complete the materials at home within 7 days of discharge. A group of 100 patients have a repeat QLQ-SAT32 module mailed to them to be completed within 7 days of receipt of first questionnaire.
PROJECTED ACCRUAL: A total of 640-768 patients (160-192 per stratum) will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Contacts and Locations| Belgium | |
| Institut Jules Bordet | |
| Brussels, Belgium, 1000 | |
| France | |
| Centre Alexis Vautrin | |
| Vandoeuvre-les-Nancy, France, 54511 | |
| Centre Paul Strauss | |
| Strasbourg, France, 67085 | |
| Centre Regional Francois Baclesse | |
| Caen, France, 14076 | |
| Institut Bergonie | |
| Bordeaux, France, 33076 | |
| Institut Curie - Section Medicale | |
| Paris, France, 75231 | |
| Institut Gustave Roussy | |
| Villejuif, France, F-94805 | |
| Spain | |
| Hospital De Navarra | |
| Pamplona, Spain, 31008 | |
| Sweden | |
| Sahlgrenska University Hospital | |
| Gothenburg, Sweden, S-413 45 | |
| Uppsala University Hospital | |
| Uppsala, Sweden, S-75183 | |
| United Kingdom | |
| Bristol Royal Infirmary | |
| Bristol, United Kingdom, BS2 8HW | |
| Investigator: | Anne Bredart | Institut Curie Hopital |
More Information
| Study ID Numbers: | CDR0000256317, EORTC-15012 |
| Study First Received: | September 6, 2002 |
| Last Updated: | August 19, 2009 |
| ClinicalTrials.gov Identifier: | NCT00045019 History of Changes |
| Health Authority: | United States: Federal Government |
|
unspecified adult solid tumor, protocol specific |